malifutide

Malifutide (also known as BJY-801) is a synthetic peptide and a first-in-class neuroprotective agent under development for the treatment of acute ischemic stroke. Originally co-developed by Eight Plus One Pharmaceutical and the Second Military Medical University, malifutide is a modified derivative of monocyte locomotion inhibitory factor (MLIF), an anti-inflammatory pentapeptide. It acts as a dual inhibitor of eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) and endothelial nitric oxide synthase (eNOS / NOS3). By targeting these pathways, malifutide suppresses ischemic inflammatory responses, reduces the expression of pathological adhesion molecules, and decreases the generation of tissue-damaging free radicals in the brain. The drug is currently in Phase II clinical trials in China.